Nifty
Sensex
:
:
25178.65
81287.19
-317.90 (-1.25%)
-961.42 (-1.17%)

Pharmaceuticals & Drugs - API

Rating :
55/99

BSE: 500288 | NSE: MOREPENLAB

43.67
27-Feb-2026
  • Open
  • High
  • Low
  • Previous Close
  •  44.8
  •  44.92
  •  43.3
  •  44.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  4703749
  •  206056479.8
  •  70.5
  •  33.5

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,398.94
  • 24.63
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,503.90
  • 0.46%
  • 2.00

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 35.65%
  • 1.84%
  • 50.28%
  • FII
  • DII
  • Others
  • 1.62%
  • 0.95%
  • 9.66%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 14.08
  • 8.80
  • 8.52

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.95
  • 7.99
  • 16.96

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 24.88
  • 3.98
  • 45.04

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 27.95
  • 28.44
  • 31.27

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.53
  • 3.27
  • 2.75

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 15.56
  • 16.75
  • 17.61

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Net Sales
484.16
452.78
6.93%
411.58
437.73
-5.97%
425.24
455.22
-6.59%
465.85
423.07
10.11%
Expenses
437.84
416.64
5.09%
380.88
393.66
-3.25%
401.07
403.60
-0.63%
423.61
374.69
13.06%
EBITDA
46.32
36.14
28.17%
30.70
44.07
-30.34%
24.17
51.62
-53.18%
42.24
48.38
-12.69%
EBIDTM
9.57%
7.98%
7.46%
10.07%
5.68%
11.34%
9.07%
11.44%
Other Income
3.81
5.34
-28.65%
4.64
4.99
-7.01%
4.41
3.43
28.57%
4.61
4.24
8.73%
Interest
4.32
1.34
222.39%
4.18
1.18
254.24%
4.04
1.15
251.30%
4.67
0.80
483.75%
Depreciation
10.38
4.93
110.55%
11.28
1.86
506.45%
9.03
5.73
57.59%
16.47
9.62
71.21%
PBT
35.42
35.20
0.62%
45.69
46.02
-0.72%
15.52
48.17
-67.78%
25.71
42.20
-39.08%
Tax
7.93
8.52
-6.92%
4.65
11.17
-58.37%
4.11
12.00
-65.75%
5.40
13.46
-59.88%
PAT
27.49
26.69
3.00%
41.04
34.85
17.76%
11.40
36.17
-68.48%
20.31
28.74
-29.33%
PATM
5.68%
5.89%
9.97%
7.96%
2.68%
7.95%
4.36%
6.79%
EPS
0.50
0.49
2.04%
0.75
0.64
17.19%
0.20
0.71
-71.83%
0.37
0.55
-32.73%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Net Sales
1,786.83
1,811.58
1,690.43
1,417.53
1,546.83
1,188.06
853.07
768.54
606.51
595.47
485.08
Net Sales Growth
1.02%
7.17%
19.25%
-8.36%
30.20%
39.27%
11.00%
26.72%
1.85%
22.76%
 
Cost Of Goods Sold
1,139.64
1,113.11
1,016.87
900.22
980.35
735.29
524.19
479.12
361.28
358.35
293.33
Gross Profit
647.19
698.47
673.56
517.31
566.47
452.77
328.87
289.42
245.23
237.12
191.76
GP Margin
36.22%
38.56%
39.85%
36.49%
36.62%
38.11%
38.55%
37.66%
40.43%
39.82%
39.53%
Total Expenditure
1,643.40
1,637.51
1,531.81
1,338.00
1,410.15
1,069.54
784.55
701.02
541.78
534.09
423.52
Power & Fuel Cost
-
40.62
34.09
23.78
18.93
13.00
12.56
13.18
11.08
9.84
7.64
% Of Sales
-
2.24%
2.02%
1.68%
1.22%
1.09%
1.47%
1.71%
1.83%
1.65%
1.57%
Employee Cost
-
208.91
181.47
154.68
164.25
135.59
109.91
95.36
76.53
69.69
58.29
% Of Sales
-
11.53%
10.74%
10.91%
10.62%
11.41%
12.88%
12.41%
12.62%
11.70%
12.02%
Manufacturing Exp.
-
102.62
95.75
91.70
98.99
67.21
48.92
31.28
16.21
22.36
13.33
% Of Sales
-
5.66%
5.66%
6.47%
6.40%
5.66%
5.73%
4.07%
2.67%
3.76%
2.75%
General & Admin Exp.
-
67.17
66.63
55.44
42.38
34.71
36.47
36.14
28.52
18.11
18.14
% Of Sales
-
3.71%
3.94%
3.91%
2.74%
2.92%
4.28%
4.70%
4.70%
3.04%
3.74%
Selling & Distn. Exp.
-
79.99
109.98
93.01
53.58
49.66
40.11
32.73
30.04
25.79
23.45
% Of Sales
-
4.42%
6.51%
6.56%
3.46%
4.18%
4.70%
4.26%
4.95%
4.33%
4.83%
Miscellaneous Exp.
-
25.09
27.02
19.17
51.67
34.08
12.39
13.20
18.11
29.95
23.45
% Of Sales
-
1.38%
1.60%
1.35%
3.34%
2.87%
1.45%
1.72%
2.99%
5.03%
1.93%
EBITDA
143.43
174.07
158.62
79.53
136.68
118.52
68.52
67.52
64.73
61.38
61.56
EBITDA Margin
8.03%
9.61%
9.38%
5.61%
8.84%
9.98%
8.03%
8.79%
10.67%
10.31%
12.69%
Other Income
17.47
18.36
13.97
6.13
20.10
12.07
9.48
3.67
3.72
3.72
1.20
Interest
17.21
8.34
3.71
1.98
2.43
1.79
1.98
2.11
4.36
7.56
10.50
Depreciation
47.16
28.98
33.47
27.93
27.64
30.28
36.91
39.90
34.32
33.90
35.20
PBT
122.34
155.11
135.42
55.76
126.70
98.51
39.11
29.18
29.77
23.63
17.06
Tax
22.09
37.09
38.80
17.08
25.02
1.42
5.53
0.34
0.00
0.00
-0.13
Tax Rate
18.06%
23.91%
28.65%
30.63%
19.75%
1.44%
14.14%
1.17%
0.00%
0.00%
-1.03%
PAT
100.24
118.03
96.16
38.68
101.68
97.09
33.58
28.85
29.59
23.63
12.80
PAT before Minority Interest
99.58
118.02
96.62
38.68
101.68
97.09
33.58
28.84
29.77
23.63
12.80
Minority Interest
-0.66
0.01
-0.46
0.00
0.00
0.00
0.00
0.01
-0.18
0.00
0.00
PAT Margin
5.61%
6.52%
5.69%
2.73%
6.57%
8.17%
3.94%
3.75%
4.88%
3.97%
2.64%
PAT Growth
-20.73%
22.74%
148.60%
-61.96%
4.73%
189.13%
16.40%
-2.50%
25.22%
84.61%
 
EPS
1.83
2.15
1.75
0.71
1.86
1.77
0.61
0.53
0.54
0.43
0.23

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Shareholder's Funds
1,156.23
847.23
752.91
578.56
424.75
284.06
253.09
225.94
196.26
300.28
Share Capital
109.58
102.23
102.23
95.56
89.96
89.96
89.96
89.96
89.96
209.61
Total Reserves
1,046.65
745.00
650.68
456.75
291.04
194.10
163.13
135.98
106.30
90.67
Non-Current Liabilities
90.49
43.93
36.88
35.50
30.06
28.42
23.38
20.20
17.80
57.47
Secured Loans
5.76
3.36
0.93
1.32
0.83
0.92
1.83
2.95
1.38
43.41
Unsecured Loans
20.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Provisions
39.85
33.82
29.74
28.24
25.39
23.82
19.01
14.42
13.59
11.34
Current Liabilities
500.65
402.04
321.16
456.46
403.80
351.44
339.17
340.12
324.86
166.56
Trade Payables
363.30
295.03
226.88
258.12
208.85
172.30
168.15
174.88
124.88
115.33
Other Current Liabilities
71.72
58.51
54.86
169.97
174.38
165.06
160.64
163.90
198.65
47.04
Short Term Borrowings
46.04
23.49
23.18
16.13
15.32
11.36
8.99
0.00
0.00
0.00
Short Term Provisions
19.60
25.02
16.24
12.24
5.25
2.72
1.39
1.33
1.33
4.19
Total Liabilities
1,778.10
1,293.20
1,110.49
1,070.06
858.15
663.46
615.18
585.81
538.29
523.68
Net Block
488.51
307.35
266.97
251.80
224.52
216.37
236.21
264.29
271.80
296.72
Gross Block
828.38
620.63
656.24
613.25
628.32
752.55
887.76
997.60
1,026.96
1,018.43
Accumulated Depreciation
339.87
313.28
389.27
361.45
403.79
536.18
651.55
733.31
755.15
721.72
Non Current Assets
618.73
404.16
354.33
335.75
331.36
291.29
315.71
342.37
346.34
366.53
Capital Work in Progress
28.34
24.45
17.01
14.15
1.96
0.00
0.00
0.00
0.00
0.00
Non Current Investment
7.17
1.30
0.00
0.00
1.08
1.08
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
94.47
70.82
70.07
69.53
103.52
73.55
79.22
77.81
73.69
69.82
Other Non Current Assets
0.23
0.24
0.28
0.28
0.27
0.28
0.28
0.27
0.85
0.00
Current Assets
1,159.37
889.04
756.16
734.30
526.79
372.18
299.47
243.44
191.95
157.15
Current Investments
77.81
0.00
0.00
0.00
0.00
0.00
0.02
0.22
0.00
0.00
Inventories
299.96
248.59
228.89
275.85
175.33
138.48
94.20
76.89
64.66
42.14
Sundry Debtors
324.76
324.94
263.25
250.64
181.98
137.68
133.75
121.85
92.95
87.94
Cash & Bank
49.36
52.12
56.31
45.97
67.89
38.88
32.21
5.95
7.59
4.36
Other Current Assets
407.48
16.44
7.15
5.29
101.59
57.14
39.29
38.53
26.74
22.70
Short Term Loans & Adv.
335.97
246.96
200.58
156.54
91.58
51.16
31.43
33.61
23.43
17.45
Net Current Assets
658.72
487.00
435.00
277.84
122.99
20.73
-39.70
-96.68
-132.92
-9.41
Total Assets
1,778.10
1,293.20
1,110.49
1,070.05
858.15
663.47
615.18
585.81
538.29
523.68

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Cash From Operating Activity
32.06
73.37
-91.17
-60.24
50.83
11.02
17.37
63.41
40.73
50.07
PBT
155.11
135.42
55.76
126.70
98.51
39.11
29.18
29.77
23.04
17.06
Adjustment
37.79
34.20
27.90
19.46
31.96
36.63
40.32
38.64
41.40
45.69
Changes in Working Capital
-123.69
-58.12
-158.28
-181.47
-78.18
-58.84
-51.78
-5.00
-23.72
-8.41
Cash after chg. in Working capital
69.21
111.49
-74.62
-35.31
52.29
16.89
17.71
63.41
40.73
54.34
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-37.15
-38.12
-16.55
-24.93
-1.46
-5.88
-0.34
0.00
0.00
0.13
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
-4.40
Cash From Investing Activity
-321.51
-83.30
-46.51
-31.68
-70.35
-12.46
-13.05
-26.93
-13.60
-27.30
Net Fixed Assets
-175.29
27.27
-35.47
24.52
123.41
135.60
113.16
31.96
-8.08
-7.02
Net Investments
-78.80
-8.34
-0.05
0.99
0.00
-1.07
0.20
-0.22
0.00
0.25
Others
-67.42
-102.23
-10.99
-57.19
-193.76
-146.99
-126.41
-58.67
-5.52
-20.53
Cash from Financing Activity
299.89
5.20
143.54
66.33
47.27
5.49
-0.44
-37.77
-23.72
-27.26
Net Cash Inflow / Outflow
10.44
-4.72
5.86
-25.58
27.75
4.04
3.88
-1.29
3.40
-4.49
Opening Cash & Equivalents
16.95
21.67
15.80
41.39
13.64
9.60
5.72
7.00
3.60
8.85
Closing Cash & Equivalent
27.38
16.95
21.67
15.80
41.39
13.64
9.60
5.72
7.00
4.36

Financial Ratios

Consolidated /

Standalone
Description
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Book Value (Rs.)
21.10
16.58
14.73
11.56
8.47
6.32
5.63
5.02
4.36
4.02
ROA
7.68%
8.04%
3.55%
10.55%
12.76%
5.25%
4.80%
5.30%
4.45%
2.53%
ROE
11.78%
12.08%
5.93%
21.79%
29.20%
12.50%
12.04%
14.10%
12.54%
7.35%
ROCE
15.48%
16.82%
8.40%
24.86%
27.13%
12.05%
10.01%
14.05%
10.18%
6.29%
Fixed Asset Turnover
2.50
2.65
2.23
2.49
1.72
1.04
0.82
0.60
0.58
0.49
Receivable days
65.45
63.50
66.16
51.04
49.10
58.07
60.70
64.63
55.44
53.22
Inventory Days
55.26
51.55
64.98
53.23
48.20
49.78
40.63
42.59
32.73
29.27
Payable days
107.94
93.67
98.32
86.93
94.60
79.06
88.85
103.38
82.97
83.88
Cash Conversion Cycle
12.78
21.38
32.82
17.35
2.71
28.78
12.48
3.85
5.20
-1.39
Total Debt/Equity
0.07
0.03
0.03
0.03
0.04
0.05
0.52
0.06
0.25
0.22
Interest Cover
19.59
37.50
29.15
53.22
56.09
20.71
14.83
7.83
4.13
2.21

News Update:


  • Morepen Laboratories bags contract worth Rs 825 crore
    23rd Feb 2026, 10:18 AM

    This engagement marks one of the most significant single CDMO mandates in the Company’s history, as it scales its global manufacturing footprint

    Read More
  • Morepen Laboratories - Quarterly Results
    11th Feb 2026, 00:00 AM

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.